Accelerating the Actionability of Treatment in Resected and Locally Advanced Pancreatic Cancer

What this Trial Is About

Researchers are investigating whether genetic information and proteins from tumors can help guide treatment for people with pancreatic ductal adenocarcinoma (PDAC). The study aims to find out if genetic testing results can be obtained quickly enough to influence treatment decisions and whether these results can predict how tumors respond or resist treatment. This trial is led by the British Columbia Cancer Agency and focuses on different stages of PDAC, including resectable, borderline resectable, and locally advanced cases. Participants will receive standard chemotherapy treatments such as FOLFIRINOX or gemcitabine-based regimens. They will provide samples of tumor tissue, fluid, and blood at various points during the study. Tumor samples are collected during standard surgery or optional biopsies, while fluid samples are taken during a standard laparoscopy procedure. Blood samples will be collected multiple times throughout the trial. The study is non-randomized and includes three groups based on disease stage. Throughout the study, participants will visit the clinic every four weeks for check-ups and tests, and complete questionnaires every 12 weeks. Researchers will monitor the time taken to return comprehensive genomic results, and assess treatment responses using measures like overall response rate, disease control rate, duration of response, progression-free survival, and overall survival. Participants will be followed for up to 72 months to evaluate these outcomes and ensure ongoing safety.

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment